References

1. Daytrana [package insert]. Wayne, Pa: Shire US Inc; 10/07.
2. Wigel SB, Pierce DM, Dixon CM, McGough JJ. Pharmacokinetics of methylphenidate transdermal system in children with ADHD. Poster presented at: 18th Annual US Psychiatric and Mental Health Congress; November 8, 2005; Las Vegas, Nev.
3. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9:476-485.
4. Wigal S, McGough JJ, Abikoff H, et al. Behavioral effects of methylphenidate transdermal system in children with ADHD. Poster presented at: Joint Annual Meeting of the American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child and Adolescent Psychiatry; October 21, 2005; Toronto, Ontario, Canada.
5. Data on file, Shire US Inc. SPD485004.
6. Data on file, Shire US Inc. SPD485005.
7. Data on file, Shire US Inc. SPD485011.
8. Wilens TE, Wigal SB, Abikoff H, et al. Effects of variable wear times on methylphenidate in ADHD. Poster presented at: 2006 Annual Meeting of the American Psychiatric Association; May 23, 2006; Toronto, Ontario, Canada.
9. Data on file, Shire US Inc. SPD485013.
10. Data on file, Shire US Inc. SPD485014.
11. López FA, Bukstein OG, Findling RL, et al. 12-month efficacy and tolerability of MTS in children with ADHD. Poster presented at: 2007 Annual Meeting of the American Psychiatric Association; May 23, 2007; San Diego, Calif.
12. Data on file, Shire US Inc. SPD485016.
13. Data on file, Shire US Inc. SPD485001.
14. Data on file, Shire US Inc. SPD485002.
15. Pelham WE, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522-528.
16. Data on file, Shire US Inc. SPD485010.